High-DAR Site-Specific Antibody–Drug Conjugates Enabled by a PEGylated Dual-arm β-Glucuronidase–Cleavable Linker with Improved Pharmacokinetics & In Vivo Efficacy
2:30 pm - Thursday 30th July 2026
- Understanding PEGylated bidentate β-glucuronidase–cleavable linker design
- Enabling stable site-specific ADCs at DAR 16 to achieve higher efficacy
- Highlighting PEGylation mitigation of hydrophobicity and aggregation to improve pharmacokinetics and enhance in vivo antitumor efficacy
